Ben Perry

Ben is a Venture Partner at Medicxi. Prior to joining Medicxi, Ben spent over twenty years leading small molecule discovery projects in various R&D organisations including the Drugs for Neglected Diseases initiative (DNDi, Geneva), Addex Therapeutics (Geneva) and UCB (Cambridge, UK) as well as co-founding the early-stage start-ups AiDD SA and MPC Therapeutics SA.

Ben supports a number of Medicxi portfolio companies, including My-T Bio, Cosmyc Therapeutics and Petalion Therapeutics.

Ben received an MChem from University of Wales Swansea, a PhD in organic chemistry from Imperial College London and an EMBA from IE Business School, Madrid.